Treatment with anti-PD-1 therapy has the potential to reverse immune suppression caused by activation of the PD-1/PD-L1 axis, leading to reactivation of pre-existing tumor-specific T cells and triggering responses that result in tumor rejection [33] (Figure 2). Here, CD274 is linked to neoplasm.